{"question": "In adults with type 2 diabetes and established cardiovascular disease, how do SGLT2 inhibitors compare with GLP-1 receptor agonists in reducing major adverse cardiovascular events and hospitalization for heart failure?", "topic": "Type 2 diabetes / cardiovascular outcomes", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "SGLT2 inhibitor", "GLP-1 receptor agonist", "major adverse cardiovascular events", "heart failure hospitalization", "cardiovascular outcomes"]}
{"question": "Among patients with type 2 diabetes and chronic kidney disease, what is the comparative effect of finerenone versus SGLT2 inhibitors on albuminuria reduction and progression to end-stage kidney disease?", "topic": "Diabetes / diabetic kidney disease", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "chronic kidney disease", "finerenone", "SGLT2 inhibitor", "albuminuria", "eGFR decline", "end-stage kidney disease"]}
{"question": "In people with obesity, how do GLP-1 receptor agonists compare with dual GIP/GLP-1 agonists for achieving ≥10% body weight loss and improving cardiometabolic risk factors?", "topic": "Obesity pharmacotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["obesity", "GLP-1 receptor agonist", "GIP GLP-1 dual agonist", "weight loss", "cardiometabolic risk", "HbA1c", "blood pressure", "lipids"]}
{"question": "In patients with metabolic dysfunction–associated steatotic liver disease, how do GLP-1 receptor agonists compare with pioglitazone in improving liver histology outcomes such as steatohepatitis resolution and fibrosis stage?", "topic": "MASLD/NAFLD treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["NAFLD", "NASH", "metabolic dysfunction-associated steatotic liver disease", "GLP-1 receptor agonist", "pioglitazone", "histology", "fibrosis", "steatohepatitis resolution"]}
{"question": "In adults with type 2 diabetes requiring injectable therapy, how does adding a GLP-1 receptor agonist compare with initiating basal-bolus insulin in HbA1c reduction, weight change, and hypoglycemia risk?", "topic": "Type 2 diabetes injectable strategies", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "GLP-1 receptor agonist", "basal bolus insulin", "HbA1c", "hypoglycemia", "weight change", "injectable therapy"]}
{"question": "In adults with prediabetes, what is the comparative effectiveness of structured lifestyle intervention versus metformin in preventing progression to type 2 diabetes over 2–5 years?", "topic": "Prediabetes prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["prediabetes", "lifestyle intervention", "metformin", "diabetes prevention", "progression to type 2 diabetes", "incidence"]}
{"question": "In patients with obesity and type 2 diabetes, how does bariatric/metabolic surgery compare with intensive medical therapy for long-term diabetes remission and microvascular outcomes?", "topic": "Obesity / metabolic surgery", "question_type": "efficacy_comparison", "expected_search_terms": ["bariatric surgery", "metabolic surgery", "type 2 diabetes remission", "intensive medical therapy", "microvascular complications", "retinopathy", "nephropathy"]}
{"question": "What molecular mechanisms link hepatic de novo lipogenesis to insulin resistance in metabolic dysfunction–associated steatotic liver disease?", "topic": "MASLD/NAFLD pathogenesis", "question_type": "mechanism", "expected_search_terms": ["de novo lipogenesis", "hepatic insulin resistance", "NAFLD", "SREBP-1c", "ChREBP", "lipotoxicity", "diacylglycerol", "PKC epsilon"]}
{"question": "How do alterations in gut microbiota composition and microbial metabolites contribute to obesity-related insulin resistance?", "topic": "Obesity / microbiome", "question_type": "mechanism", "expected_search_terms": ["gut microbiota", "obesity", "insulin resistance", "short-chain fatty acids", "bile acids", "endotoxemia", "metabolites", "inflammation"]}
{"question": "What is the role of adipose tissue macrophage polarization and inflammatory cytokine signaling in the development of insulin resistance in obesity?", "topic": "Obesity inflammation", "question_type": "mechanism", "expected_search_terms": ["adipose tissue macrophages", "M1 M2 polarization", "TNF-alpha", "IL-6", "insulin resistance", "obesity", "inflammation", "NF-kappaB"]}
{"question": "How does skeletal muscle mitochondrial dysfunction contribute to impaired glucose uptake and insulin resistance in type 2 diabetes?", "topic": "Type 2 diabetes mechanisms", "question_type": "mechanism", "expected_search_terms": ["skeletal muscle", "mitochondrial dysfunction", "insulin resistance", "glucose uptake", "GLUT4", "oxidative phosphorylation", "type 2 diabetes"]}
{"question": "What is the association between long-term exposure to fine particulate air pollution (PM2.5) and incident type 2 diabetes in population-based cohorts?", "topic": "Diabetes epidemiology / environmental exposure", "question_type": "epidemiology", "expected_search_terms": ["PM2.5", "air pollution", "incident type 2 diabetes", "cohort", "hazard ratio", "environmental exposure", "epidemiology"]}
{"question": "How does gestational diabetes mellitus affect the subsequent risk of type 2 diabetes in mothers within 5–15 years postpartum?", "topic": "Diabetes epidemiology / pregnancy", "question_type": "epidemiology", "expected_search_terms": ["gestational diabetes", "postpartum", "type 2 diabetes risk", "incidence", "follow-up", "cohort study"]}
{"question": "What is the relationship between obstructive sleep apnea severity and risk of incident metabolic dysfunction–associated steatotic liver disease or fibrosis progression?", "topic": "MASLD/NAFLD epidemiology / comorbidity", "question_type": "epidemiology", "expected_search_terms": ["obstructive sleep apnea", "NAFLD", "NASH", "liver fibrosis", "severity", "apnea hypopnea index", "incident", "progression"]}
{"question": "In adults with metabolic dysfunction–associated steatotic liver disease, how do genetic variants in lipid metabolism genes influence the prevalence of advanced fibrosis across ethnic groups?", "topic": "MASLD/NAFLD genetics", "question_type": "epidemiology", "expected_search_terms": ["NAFLD genetics", "advanced fibrosis", "PNPLA3", "TM6SF2", "ethnic differences", "prevalence", "risk allele"]}
{"question": "Among individuals with type 2 diabetes, how strongly does baseline albuminuria predict subsequent cardiovascular mortality independent of estimated glomerular filtration rate?", "topic": "Diabetes prognosis / cardiorenal risk", "question_type": "prognosis", "expected_search_terms": ["type 2 diabetes", "albuminuria", "cardiovascular mortality", "prognosis", "eGFR", "risk prediction", "cohort"]}
{"question": "In metabolic dysfunction–associated steatotic liver disease, how well do noninvasive fibrosis scores predict future liver-related events such as decompensation or hepatocellular carcinoma?", "topic": "MASLD/NAFLD prognosis", "question_type": "prognosis", "expected_search_terms": ["NAFLD", "noninvasive fibrosis score", "FIB-4", "NAFLD fibrosis score", "liver decompensation", "hepatocellular carcinoma", "prediction", "outcomes"]}
{"question": "In adults with obesity, what baseline clinical factors predict long-term weight regain after initial successful weight loss achieved by diet-based interventions?", "topic": "Obesity prognosis / weight maintenance", "question_type": "prognosis", "expected_search_terms": ["obesity", "weight regain", "weight maintenance", "predictors", "diet intervention", "follow-up", "behavioral factors"]}
{"question": "What is the evidence that time-restricted eating improves insulin sensitivity and hepatic steatosis compared with calorie restriction alone in adults with overweight or metabolic syndrome?", "topic": "Metabolic syndrome / dietary interventions", "question_type": "review", "expected_search_terms": ["time-restricted eating", "intermittent fasting", "calorie restriction", "insulin sensitivity", "hepatic steatosis", "metabolic syndrome", "randomized trial"]}
{"question": "What are the benefits and harms of metformin use in people with metabolic dysfunction–associated steatotic liver disease without diabetes on liver fat content and fibrosis markers?", "topic": "MASLD/NAFLD pharmacotherapy", "question_type": "review", "expected_search_terms": ["metformin", "NAFLD", "non-diabetic", "liver fat", "fibrosis markers", "ALT", "MRI-PDFF", "randomized controlled trial"]}
{"question": "In non-hospitalized adults at high risk for severe COVID-19, how does nirmatrelvir/ritonavir compare with molnupiravir in preventing hospitalization or death, and how do their adverse event profiles differ?", "topic": "COVID-19 therapeutics", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "nirmatrelvir ritonavir", "Paxlovid", "molnupiravir", "outpatients", "hospitalization", "mortality", "adverse events", "comparative effectiveness"]}
{"question": "Among hospitalized patients with severe COVID-19 requiring oxygen, how do outcomes differ between tocilizumab and baricitinib when added to corticosteroids?", "topic": "COVID-19 immunomodulators", "question_type": "efficacy_comparison", "expected_search_terms": ["severe COVID-19", "tocilizumab", "baricitinib", "corticosteroids", "oxygen therapy", "mortality", "mechanical ventilation", "randomized", "observational"]}
{"question": "How does SARS-CoV-2 infection of endothelial cells contribute to microvascular thrombosis and organ injury in COVID-19?", "topic": "COVID-19 pathogenesis", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "endothelial infection", "endotheliitis", "microthrombosis", "coagulopathy", "NETs", "complement", "organ injury"]}
{"question": "What is the association between SARS-CoV-2 viral load kinetics (including Ct values) and transmissibility across different variants in community settings?", "topic": "COVID-19 transmission", "question_type": "epidemiology", "expected_search_terms": ["SARS-CoV-2", "viral load", "Ct value", "kinetics", "transmissibility", "secondary attack rate", "variants", "Omicron", "Delta"]}
{"question": "In immunocompromised individuals, how durable are neutralizing antibody responses after mRNA COVID-19 vaccination and what factors predict poor serologic response?", "topic": "COVID-19 vaccines in immunocompromised hosts", "question_type": "prognosis", "expected_search_terms": ["mRNA vaccine", "COVID-19", "immunocompromised", "transplant", "anti-CD20", "neutralizing antibodies", "durability", "predictors", "serologic response"]}
{"question": "How effective is pre-exposure prophylaxis with long-acting monoclonal antibodies in preventing symptomatic COVID-19 among severely immunocompromised patients in the era of Omicron subvariants?", "topic": "COVID-19 prevention", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "pre-exposure prophylaxis", "monoclonal antibody", "tixagevimab cilgavimab", "immunocompromised", "Omicron", "breakthrough infection", "effectiveness"]}
{"question": "What is the incidence of post-acute sequelae of SARS-CoV-2 infection (long COVID) after breakthrough infections in vaccinated adults, and which baseline factors predict persistence of symptoms?", "topic": "Long COVID", "question_type": "epidemiology", "expected_search_terms": ["long COVID", "post-acute sequelae", "breakthrough infection", "vaccinated", "incidence", "risk factors", "cohort", "symptom persistence"]}
{"question": "In patients hospitalized with COVID-19, how does therapeutic-dose anticoagulation compare with prophylactic-dose anticoagulation in reducing thrombotic events and mortality while affecting bleeding risk?", "topic": "COVID-19 anticoagulation", "question_type": "efficacy_comparison", "expected_search_terms": ["COVID-19", "therapeutic anticoagulation", "prophylactic anticoagulation", "thrombosis", "bleeding", "mortality", "hospitalized", "randomized trial"]}
{"question": "What mechanisms drive persistent SARS-CoV-2 antigen or RNA detection in tissue reservoirs and how might this relate to long COVID pathophysiology?", "topic": "Long COVID mechanisms", "question_type": "mechanism", "expected_search_terms": ["SARS-CoV-2", "tissue reservoirs", "persistent antigen", "viral persistence", "gut", "brain", "long COVID", "pathophysiology"]}
{"question": "Among people living with HIV, how does integrase inhibitor-based antiretroviral therapy compare with non-nucleoside reverse transcriptase inhibitor-based therapy in risk of weight gain and metabolic syndrome?", "topic": "HIV antiretroviral therapy safety", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV", "integrase inhibitor", "dolutegravir", "bictegravir", "NNRTI", "weight gain", "metabolic syndrome", "comparative", "cohort"]}
{"question": "In HIV infection, how does early initiation of antiretroviral therapy influence the size of the latent reservoir as measured by integrated HIV DNA or replication-competent virus assays?", "topic": "HIV cure research", "question_type": "mechanism", "expected_search_terms": ["HIV", "early ART", "latent reservoir", "integrated HIV DNA", "viral outgrowth assay", "replication competent", "reservoir size"]}
{"question": "What is the effectiveness of long-acting injectable cabotegravir compared with daily oral tenofovir/emtricitabine for HIV pre-exposure prophylaxis in preventing incident HIV infection across different risk groups?", "topic": "HIV prevention (PrEP)", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV PrEP", "cabotegravir", "long-acting injectable", "tenofovir emtricitabine", "daily oral", "effectiveness", "incidence", "risk groups"]}
{"question": "Among individuals with HIV and tuberculosis coinfection, how do dolutegravir-based regimens compare with efavirenz-based regimens in virologic suppression and treatment-limiting adverse events during rifampin therapy?", "topic": "HIV/TB coinfection", "question_type": "efficacy_comparison", "expected_search_terms": ["HIV tuberculosis coinfection", "dolutegravir", "efavirenz", "rifampin", "drug interactions", "virologic suppression", "adverse events"]}
{"question": "What host and viral factors predict progression from acute HIV infection to faster CD4 decline or earlier AIDS-defining illness in the absence of immediate therapy?", "topic": "HIV natural history", "question_type": "prognosis", "expected_search_terms": ["acute HIV infection", "CD4 decline", "viral set point", "HLA", "co-receptor usage", "prognostic factors", "progression", "AIDS"]}
{"question": "How do broadly neutralizing antibodies exert antiviral effects in HIV infection beyond neutralization, including Fc-mediated effector functions and impacts on the viral reservoir?", "topic": "HIV immunotherapy", "question_type": "mechanism", "expected_search_terms": ["HIV", "broadly neutralizing antibodies", "Fc effector function", "ADCC", "phagocytosis", "viral reservoir", "immunotherapy"]}
{"question": "In community and hospital settings, what is the association between prior antibiotic exposure and subsequent infection or colonization with carbapenem-resistant Enterobacterales?", "topic": "Antibiotic-resistant infections (CRE)", "question_type": "epidemiology", "expected_search_terms": ["carbapenem-resistant Enterobacterales", "CRE", "antibiotic exposure", "risk factors", "colonization", "infection", "case-control", "cohort"]}
{"question": "For bloodstream infections caused by carbapenem-resistant Enterobacterales, how do ceftazidime-avibactam and meropenem-vaborbactam compare in mortality outcomes and emergence of resistance during therapy?", "topic": "Antibiotic-resistant infections treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["CRE bacteremia", "ceftazidime-avibactam", "meropenem-vaborbactam", "mortality", "clinical outcomes", "resistance emergence", "KPC"]}
{"question": "What bacterial genetic and physiological mechanisms contribute to heteroresistance to vancomycin in Staphylococcus aureus, and how is heteroresistance detected in clinical laboratories?", "topic": "MRSA/VISA mechanisms", "question_type": "mechanism", "expected_search_terms": ["Staphylococcus aureus", "vancomycin", "heteroresistance", "hVISA", "cell wall thickening", "genetics", "population analysis profile", "laboratory detection"]}
{"question": "In complicated urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacterales, how does piperacillin-tazobactam compare with carbapenems in clinical cure and mortality?", "topic": "ESBL infections treatment", "question_type": "efficacy_comparison", "expected_search_terms": ["ESBL", "Enterobacterales", "complicated urinary tract infection", "piperacillin-tazobactam", "carbapenem", "clinical cure", "mortality", "comparative study"]}
{"question": "What is the effectiveness of hospital antimicrobial stewardship interventions (such as prospective audit-and-feedback or formulary restriction) in reducing rates of Clostridioides difficile infection and multidrug-resistant organism infections?", "topic": "Antimicrobial stewardship", "question_type": "review", "expected_search_terms": ["antimicrobial stewardship", "audit and feedback", "formulary restriction", "Clostridioides difficile", "multidrug-resistant organisms", "hospital", "effectiveness", "systematic review"]}
{"question": "In first-line metastatic non-small cell lung cancer with high PD-L1 expression, how does PD-1/PD-L1 inhibitor monotherapy compare with chemo-immunotherapy in overall survival and immune-related adverse events?", "topic": "Immunotherapy (NSCLC)", "question_type": "efficacy_comparison", "expected_search_terms": ["NSCLC", "high PD-L1", "PD-1 inhibitor", "PD-L1 inhibitor", "chemoimmunotherapy", "overall survival", "immune-related adverse events"]}
{"question": "In advanced renal cell carcinoma, how do outcomes and toxicity differ between dual immune checkpoint blockade (PD-1 plus CTLA-4) and PD-1 inhibitor plus VEGF-targeted therapy?", "topic": "Immunotherapy vs targeted combinations (RCC)", "question_type": "efficacy_comparison", "expected_search_terms": ["renal cell carcinoma", "PD-1", "CTLA-4", "dual checkpoint", "VEGF inhibitor", "combination therapy", "progression-free survival", "toxicity"]}
{"question": "In HER2-positive metastatic breast cancer after progression on trastuzumab-based therapy, how does trastuzumab deruxtecan compare with other HER2-targeted regimens for response rate and interstitial lung disease risk?", "topic": "Targeted therapy (HER2 breast cancer)", "question_type": "efficacy_comparison", "expected_search_terms": ["HER2-positive", "metastatic breast cancer", "trastuzumab deruxtecan", "HER2 targeted therapy", "response rate", "interstitial lung disease", "pneumonitis"]}
{"question": "In BRAF V600-mutant metastatic melanoma, how does first-line BRAF/MEK targeted therapy compare with immune checkpoint blockade in overall survival and durability of response?", "topic": "Targeted therapy vs immunotherapy (melanoma)", "question_type": "efficacy_comparison", "expected_search_terms": ["melanoma", "BRAF V600", "BRAF inhibitor", "MEK inhibitor", "immune checkpoint inhibitor", "overall survival", "durable response"]}
{"question": "In ALK-rearranged metastatic non-small cell lung cancer, how do next-generation ALK inhibitors compare in intracranial response and time to central nervous system progression?", "topic": "Targeted therapy (ALK NSCLC)", "question_type": "efficacy_comparison", "expected_search_terms": ["ALK-rearranged", "NSCLC", "ALK inhibitor", "intracranial response", "brain metastases", "CNS progression"]}
{"question": "In EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors, what is the clinical efficacy of targeting MET amplification versus using chemotherapy-based regimens?", "topic": "Resistance and subsequent therapy (EGFR NSCLC)", "question_type": "efficacy_comparison", "expected_search_terms": ["EGFR-mutant NSCLC", "acquired resistance", "MET amplification", "MET inhibitor", "chemotherapy", "post-EGFR TKI"]}
{"question": "In castration-resistant prostate cancer, how does PARP inhibitor therapy benefit differ between tumors with BRCA1/2 alterations and tumors with other homologous recombination repair gene alterations?", "topic": "Targeted therapy biomarkers (prostate cancer)", "question_type": "efficacy_comparison", "expected_search_terms": ["castration-resistant prostate cancer", "PARP inhibitor", "BRCA1", "BRCA2", "homologous recombination repair", "biomarker", "response"]}
{"question": "In IDH1-mutant cholangiocarcinoma, what clinical benefit is associated with IDH1 inhibition compared with standard second-line chemotherapy outcomes?", "topic": "Targeted therapy (cholangiocarcinoma)", "question_type": "efficacy_comparison", "expected_search_terms": ["cholangiocarcinoma", "IDH1 mutation", "IDH1 inhibitor", "second-line", "chemotherapy", "progression-free survival"]}
{"question": "In patients with metastatic colorectal cancer, how does anti-EGFR therapy efficacy differ between left-sided versus right-sided primary tumors in RAS wild-type disease?", "topic": "Predictive factors for targeted therapy (CRC)", "question_type": "prognosis", "expected_search_terms": ["metastatic colorectal cancer", "anti-EGFR", "cetuximab", "panitumumab", "RAS wild-type", "left-sided", "right-sided", "response"]}
{"question": "In triple-negative breast cancer treated with immune checkpoint inhibitors, how do PD-L1 assay type and scoring method influence patient selection and observed clinical benefit?", "topic": "Biomarkers (TNBC immunotherapy)", "question_type": "review", "expected_search_terms": ["triple-negative breast cancer", "PD-L1 assay", "scoring", "immune checkpoint inhibitor", "patient selection", "predictive biomarker"]}
{"question": "What mechanisms drive resistance to PD-1/PD-L1 blockade through loss of antigen presentation (e.g., HLA or beta-2 microglobulin alterations) across solid tumors?", "topic": "Mechanisms of immunotherapy resistance", "question_type": "mechanism", "expected_search_terms": ["PD-1 resistance", "PD-L1 resistance", "antigen presentation", "HLA loss", "beta-2 microglobulin", "immune evasion", "solid tumor"]}
{"question": "How does activation of the WNT/β-catenin pathway contribute to immune checkpoint inhibitor resistance via T-cell exclusion in solid tumors?", "topic": "Tumor microenvironment mechanisms", "question_type": "mechanism", "expected_search_terms": ["WNT", "beta-catenin", "T-cell exclusion", "immune checkpoint resistance", "tumor microenvironment", "CD8 infiltration"]}
{"question": "What evidence supports the role of tumor-associated macrophage polarization in mediating resistance to immune checkpoint blockade, and which therapeutic strategies can reprogram macrophages?", "topic": "Microenvironment-targeting strategies", "question_type": "review", "expected_search_terms": ["tumor-associated macrophages", "M2 polarization", "checkpoint inhibitor resistance", "CSF1R", "CD40 agonist", "macrophage reprogramming"]}
{"question": "In hematologic malignancies, what are the key mechanisms of resistance to CAR T-cell therapy related to antigen loss or modulation?", "topic": "Cell therapy resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["CAR T", "resistance", "antigen loss", "antigen modulation", "CD19", "hematologic malignancy", "relapse"]}
{"question": "What molecular mechanisms underlie platinum chemotherapy resistance mediated by enhanced nucleotide excision repair and homologous recombination in ovarian cancer?", "topic": "Chemotherapy resistance mechanisms (ovarian cancer)", "question_type": "mechanism", "expected_search_terms": ["ovarian cancer", "platinum resistance", "nucleotide excision repair", "homologous recombination", "DNA repair", "cisplatin resistance"]}
{"question": "In estrogen receptor-positive breast cancer, how does ESR1 mutation status affect response to aromatase inhibitors versus selective estrogen receptor degraders in the metastatic setting?", "topic": "Endocrine therapy resistance (breast cancer)", "question_type": "efficacy_comparison", "expected_search_terms": ["ER-positive breast cancer", "ESR1 mutation", "aromatase inhibitor", "SERD", "metastatic", "endocrine resistance"]}
{"question": "In gastrointestinal stromal tumors, what is the spectrum of secondary KIT or PDGFRA mutations associated with resistance to first-line KIT inhibition, and how does it guide subsequent targeted therapy choice?", "topic": "Targeted therapy resistance (GIST)", "question_type": "review", "expected_search_terms": ["gastrointestinal stromal tumor", "KIT", "PDGFRA", "secondary mutation", "imatinib resistance", "targeted therapy sequencing"]}
{"question": "What is the incidence and clinical impact of hyperprogressive disease after initiation of immune checkpoint inhibitors across different solid tumors?", "topic": "Immunotherapy epidemiology and outcomes", "question_type": "epidemiology", "expected_search_terms": ["hyperprogressive disease", "immune checkpoint inhibitor", "incidence", "solid tumors", "clinical outcomes", "risk factors"]}
{"question": "In patients receiving immune checkpoint inhibitors, how does baseline corticosteroid use for cancer-related symptoms associate with treatment response and overall survival?", "topic": "Immunotherapy outcomes modifiers", "question_type": "prognosis", "expected_search_terms": ["immune checkpoint inhibitor", "baseline corticosteroids", "overall survival", "response", "cancer-related symptoms", "prognostic factor"]}
{"question": "How do gut microbiome composition and antibiotic exposure influence response rates and toxicity to immune checkpoint inhibitors in solid tumors?", "topic": "Host factors in immunotherapy response", "question_type": "mechanism", "expected_search_terms": ["gut microbiome", "antibiotics", "immune checkpoint inhibitors", "response", "toxicity", "solid tumors", "dysbiosis"]}
{"question": "In people with cystic fibrosis who have at least one F508del CFTR variant, how do triple CFTR modulator regimens compare with dual CFTR modulator regimens in improving percent predicted FEV1 and reducing pulmonary exacerbations?", "topic": "Cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "triple therapy", "dual therapy", "F508del", "FEV1", "pulmonary exacerbation"]}
{"question": "What is the evidence that CFTR modulators improve exocrine pancreatic function (e.g., fecal elastase, pancreatitis risk) in cystic fibrosis, and which genotypes or age groups show the greatest change?", "topic": "Cystic fibrosis", "question_type": "review", "expected_search_terms": ["cystic fibrosis", "CFTR modulators", "pancreatic insufficiency", "fecal elastase", "pancreatitis", "genotype", "age"]}
{"question": "In cystic fibrosis, how does long-term azithromycin therapy compare to inhaled antibiotics in preventing pulmonary exacerbations and slowing lung function decline?", "topic": "Cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "azithromycin", "inhaled antibiotics", "tobramycin", "aztreonam", "pulmonary exacerbation", "lung function decline"]}
{"question": "How does early initiation of CFTR modulator therapy in children with cystic fibrosis affect the incidence of bronchiectasis as measured by imaging outcomes?", "topic": "Cystic fibrosis", "question_type": "prognosis", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "early initiation", "children", "bronchiectasis", "CT", "MRI", "structural lung disease"]}
{"question": "What mechanisms link CFTR dysfunction to impaired airway surface liquid hydration and mucociliary clearance, and which molecular pathways are most consistently supported by experimental studies?", "topic": "Cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["CFTR dysfunction", "airway surface liquid", "mucociliary clearance", "ion transport", "ENaC", "pathway", "mechanism"]}
{"question": "Among adults with cystic fibrosis, what is the prevalence and clinical impact of cystic fibrosis–related diabetes on mortality and lung function decline in contemporary cohorts?", "topic": "Cystic fibrosis", "question_type": "epidemiology", "expected_search_terms": ["cystic fibrosis", "cystic fibrosis-related diabetes", "prevalence", "mortality", "lung function decline", "cohort"]}
{"question": "In cystic fibrosis with chronic Pseudomonas aeruginosa infection, how does inhaled hypertonic saline compare with dornase alfa for improving lung function and reducing exacerbation frequency?", "topic": "Cystic fibrosis", "question_type": "efficacy_comparison", "expected_search_terms": ["cystic fibrosis", "hypertonic saline", "dornase alfa", "Pseudomonas aeruginosa", "FEV1", "exacerbation"]}
{"question": "How do airway microbiome changes after CFTR modulator therapy correlate with clinical response in cystic fibrosis, including exacerbation rates and inflammation biomarkers?", "topic": "Cystic fibrosis", "question_type": "mechanism", "expected_search_terms": ["cystic fibrosis", "CFTR modulator", "airway microbiome", "microbiota", "inflammation biomarkers", "exacerbations", "clinical response"]}
{"question": "In amyotrophic lateral sclerosis, how does combined riluzole plus edaravone therapy compare with riluzole alone in slowing functional decline measured by ALSFRS-R?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "ALS", "riluzole", "edaravone", "combination therapy", "ALSFRS-R", "functional decline"]}
{"question": "What is the strength of evidence that neurofilament light chain levels predict disease progression and survival in amyotrophic lateral sclerosis?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "neurofilament light", "NfL", "biomarker", "prognosis", "survival", "progression"]}
{"question": "How do genetic variants in C9orf72 versus SOD1 influence clinical phenotype and survival in amyotrophic lateral sclerosis across observational cohorts?", "topic": "ALS", "question_type": "prognosis", "expected_search_terms": ["amyotrophic lateral sclerosis", "C9orf72", "SOD1", "genotype phenotype", "survival", "clinical features", "cohort"]}
{"question": "What mechanisms are most supported for TDP-43 pathology driving motor neuron degeneration in amyotrophic lateral sclerosis, including RNA processing defects and proteostasis impairment?", "topic": "ALS", "question_type": "mechanism", "expected_search_terms": ["ALS", "TDP-43", "motor neuron degeneration", "RNA processing", "proteostasis", "aggregation", "mechanism"]}
{"question": "In amyotrophic lateral sclerosis, what is the epidemiologic evidence for environmental or occupational risk factors such as pesticide exposure, military service, or heavy metal exposure?", "topic": "ALS", "question_type": "epidemiology", "expected_search_terms": ["amyotrophic lateral sclerosis", "risk factors", "environmental exposure", "pesticides", "military", "heavy metals", "epidemiology"]}
{"question": "In amyotrophic lateral sclerosis, how does early initiation of noninvasive ventilation compare with standard timing in terms of survival and quality-of-life outcomes?", "topic": "ALS", "question_type": "efficacy_comparison", "expected_search_terms": ["amyotrophic lateral sclerosis", "noninvasive ventilation", "early initiation", "survival", "quality of life", "respiratory support"]}
{"question": "What is the evidence that feeding tube placement (e.g., gastrostomy) improves survival or reduces complications in amyotrophic lateral sclerosis patients with dysphagia?", "topic": "ALS", "question_type": "review", "expected_search_terms": ["amyotrophic lateral sclerosis", "gastrostomy", "PEG", "feeding tube", "dysphagia", "survival", "complications"]}
{"question": "In Huntington's disease, how do vesicular monoamine transporter 2 (VMAT2) inhibitors compare with atypical antipsychotics for reducing chorea severity and neuropsychiatric adverse effects?", "topic": "Huntington's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Huntington disease", "chorea", "VMAT2 inhibitor", "tetrabenazine", "deutetrabenazine", "atypical antipsychotic", "adverse effects"]}
{"question": "How well does CAG repeat length predict age at onset and rate of progression in Huntington's disease in longitudinal cohort studies?", "topic": "Huntington's disease", "question_type": "prognosis", "expected_search_terms": ["Huntington disease", "CAG repeat length", "age at onset", "disease progression", "longitudinal cohort", "predictive factors"]}
{"question": "What mechanisms connect mutant huntingtin to synaptic dysfunction and striatal neuron vulnerability, and which pathways (e.g., BDNF transport, mitochondrial dysfunction) have the strongest experimental support?", "topic": "Huntington's disease", "question_type": "mechanism", "expected_search_terms": ["Huntington disease", "mutant huntingtin", "synaptic dysfunction", "striatal neurons", "BDNF", "mitochondrial dysfunction", "mechanism"]}
{"question": "In Huntington's disease, what is the evidence that structured exercise or multidisciplinary rehabilitation slows functional decline or improves motor outcomes?", "topic": "Huntington's disease", "question_type": "review", "expected_search_terms": ["Huntington disease", "exercise", "rehabilitation", "physical therapy", "motor outcomes", "functional decline", "randomized trial"]}
{"question": "What is the prevalence and incidence of psychiatric manifestations (depression, irritability, psychosis) in prodromal versus manifest Huntington's disease, and how do they relate to subsequent functional decline?", "topic": "Huntington's disease", "question_type": "epidemiology", "expected_search_terms": ["Huntington disease", "prodromal", "psychiatric symptoms", "depression", "irritability", "psychosis", "incidence", "prevalence", "functional decline"]}
{"question": "In first-line treatment of metastatic non-small cell lung cancer without actionable driver mutations, how do overall survival and grade ≥3 adverse events compare between PD-1/PD-L1 inhibitor plus platinum-doublet chemotherapy versus PD-1/PD-L1 inhibitor monotherapy?", "topic": "Immuno-oncology phase III comparative efficacy", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic non-small cell lung cancer", "PD-1", "PD-L1", "platinum chemotherapy", "phase III", "overall survival", "grade 3 adverse events", "first-line"]}
{"question": "In hormone receptor–positive, HER2-negative advanced breast cancer, how does progression-free survival compare between CDK4/6 inhibitor plus endocrine therapy versus endocrine therapy alone in phase III randomized trials?", "topic": "Targeted therapy phase III efficacy", "question_type": "efficacy_comparison", "expected_search_terms": ["HR-positive", "HER2-negative", "advanced breast cancer", "CDK4/6 inhibitor", "endocrine therapy", "phase III", "progression-free survival", "randomized"]}
{"question": "In patients with atrial fibrillation, how do major bleeding rates compare between direct oral anticoagulants and warfarin in phase III trials, and how does renal function stratification modify these outcomes?", "topic": "Anticoagulant development and safety in phase III", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "direct oral anticoagulant", "warfarin", "phase III", "major bleeding", "renal impairment", "subgroup analysis"]}
{"question": "In chronic hepatitis C treatment, how do sustained virologic response rates and drug–drug interaction profiles differ between pan-genotypic direct-acting antiviral regimens in phase III studies?", "topic": "Antiviral drug development and interactions", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatitis C", "pan-genotypic", "direct-acting antiviral", "phase III", "SVR12", "drug-drug interactions", "CYP", "P-gp"]}
{"question": "In type 2 diabetes with established cardiovascular disease or high risk, how do major adverse cardiovascular event outcomes compare between GLP-1 receptor agonists and SGLT2 inhibitors across cardiovascular outcomes trials?", "topic": "Cardiometabolic outcomes trials", "question_type": "efficacy_comparison", "expected_search_terms": ["type 2 diabetes", "GLP-1 receptor agonist", "SGLT2 inhibitor", "cardiovascular outcomes trial", "MACE", "phase III", "randomized"]}
{"question": "In moderate-to-severe ulcerative colitis, how do induction and maintenance remission rates compare between JAK inhibitors and anti-TNF biologics in phase III randomized trials?", "topic": "Immunology drug development (IBD)", "question_type": "efficacy_comparison", "expected_search_terms": ["ulcerative colitis", "JAK inhibitor", "anti-TNF", "phase III", "induction", "maintenance", "clinical remission", "randomized trial"]}
{"question": "In relapsing-remitting multiple sclerosis, how do annualized relapse rates and serious infection risks compare between anti-CD20 monoclonal antibodies and S1P receptor modulators in phase III trials?", "topic": "Neuroimmunology comparative phase III evidence", "question_type": "efficacy_comparison", "expected_search_terms": ["relapsing-remitting multiple sclerosis", "anti-CD20", "S1P receptor modulator", "phase III", "annualized relapse rate", "serious infections"]}
{"question": "In metastatic colorectal cancer, does adding an EGFR inhibitor to first-line chemotherapy improve overall survival compared with adding a VEGF inhibitor, and how does RAS/RAF mutation status influence efficacy in phase III trials?", "topic": "Oncology targeted therapy trials and biomarkers", "question_type": "efficacy_comparison", "expected_search_terms": ["metastatic colorectal cancer", "EGFR inhibitor", "VEGF inhibitor", "first-line", "phase III", "overall survival", "RAS mutation", "BRAF mutation"]}
{"question": "In chronic heart failure with reduced ejection fraction, how do hospitalization and mortality outcomes compare between angiotensin receptor–neprilysin inhibitor therapy and ACE inhibitor therapy in large randomized trials?", "topic": "Cardiology phase III outcomes trials", "question_type": "efficacy_comparison", "expected_search_terms": ["heart failure reduced ejection fraction", "angiotensin receptor neprilysin inhibitor", "ACE inhibitor", "randomized", "hospitalization", "mortality", "phase III"]}
{"question": "In acute ischemic stroke due to large vessel occlusion, what is the effect of extending the thrombectomy time window on functional independence compared with standard time windows in randomized clinical trials?", "topic": "Acute neurovascular trials", "question_type": "efficacy_comparison", "expected_search_terms": ["acute ischemic stroke", "large vessel occlusion", "mechanical thrombectomy", "extended time window", "randomized trial", "functional independence", "mRS"]}
{"question": "What pharmacokinetic mechanisms explain clinically significant interactions between CYP3A4 inhibitors and oral targeted anticancer therapies, and which interaction-management strategies are supported by clinical trial data?", "topic": "Drug–drug interaction mechanisms in oncology development", "question_type": "mechanism", "expected_search_terms": ["CYP3A4 inhibitor", "oral targeted therapy", "pharmacokinetics", "drug-drug interaction", "dose adjustment", "clinical trial", "exposure"]}
{"question": "How does P-glycoprotein transporter modulation affect the absorption and exposure of direct oral anticoagulants, and what interaction risks are reported with common cardiovascular co-medications?", "topic": "Transporter-mediated drug interactions in phase III-era drugs", "question_type": "mechanism", "expected_search_terms": ["P-glycoprotein", "direct oral anticoagulant", "pharmacokinetics", "drug interaction", "amiodarone", "verapamil", "diltiazem", "rivaroxaban", "apixaban", "dabigatran"]}
{"question": "In tuberculosis therapy development, what evidence supports rifampin-mediated enzyme induction as a key driver of reduced exposure to co-administered drugs, and which classes are most affected in clinical studies?", "topic": "Enzyme induction interactions affecting clinical trials", "question_type": "mechanism", "expected_search_terms": ["rifampin", "enzyme induction", "CYP induction", "drug-drug interaction", "pharmacokinetics", "tuberculosis", "co-administered drugs"]}
{"question": "Among adults enrolled in phase III trials of biologics for psoriasis, what is the incidence of herpes zoster and serious infections, and how does it differ by mechanism of action (anti-TNF vs IL-17 vs IL-23 inhibitors)?", "topic": "Safety epidemiology within phase III programs", "question_type": "epidemiology", "expected_search_terms": ["psoriasis", "biologic", "phase III", "herpes zoster", "serious infection", "anti-TNF", "IL-17 inhibitor", "IL-23 inhibitor", "incidence"]}
{"question": "In phase III trials for Alzheimer’s disease disease-modifying therapies, what is the reported incidence and clinical spectrum of amyloid-related imaging abnormalities, and which baseline factors predict higher risk?", "topic": "Adverse event epidemiology and predictors in phase III", "question_type": "epidemiology", "expected_search_terms": ["Alzheimer disease", "phase III", "amyloid-related imaging abnormalities", "ARIA-E", "ARIA-H", "incidence", "risk factors", "baseline predictors"]}
{"question": "In oncology phase III trials of antibody–drug conjugates, what is the frequency of interstitial lung disease/pneumonitis and what trial-level factors are associated with higher rates?", "topic": "Safety signal characterization in late-stage oncology trials", "question_type": "epidemiology", "expected_search_terms": ["antibody-drug conjugate", "phase III", "interstitial lung disease", "pneumonitis", "incidence", "risk factors", "oncology"]}
{"question": "In chronic myeloid leukemia treated with tyrosine kinase inhibitors, how does early molecular response predict long-term outcomes such as progression-free survival across clinical trial cohorts?", "topic": "Surrogate endpoints and prognosis in clinical trials", "question_type": "prognosis", "expected_search_terms": ["chronic myeloid leukemia", "tyrosine kinase inhibitor", "early molecular response", "BCR-ABL", "prognostic", "progression-free survival", "clinical trial"]}
{"question": "In metastatic castration-resistant prostate cancer, how well do PSA declines and radiographic progression-free survival predict overall survival benefit in phase III trials of novel androgen receptor pathway inhibitors?", "topic": "Endpoint validation in phase III oncology trials", "question_type": "prognosis", "expected_search_terms": ["metastatic castration-resistant prostate cancer", "androgen receptor inhibitor", "PSA decline", "radiographic progression-free survival", "overall survival", "phase III", "surrogate endpoint"]}
{"question": "What design choices in phase III non-inferiority antibiotic trials (margin selection, endpoint definitions, analysis populations) most strongly influence the likelihood of concluding non-inferiority?", "topic": "Clinical trial design methodology for drug development", "question_type": "review", "expected_search_terms": ["non-inferiority trial", "antibiotics", "phase III", "noninferiority margin", "endpoint definition", "per-protocol", "intention-to-treat", "trial design"]}
{"question": "What evidence from phase III trials supports or refutes clinically meaningful pharmacodynamic interactions between proton pump inhibitors and oral anticancer agents with pH-dependent solubility, and what mitigation strategies are recommended?", "topic": "Drug–drug interactions impacting clinical efficacy in phase III context", "question_type": "review", "expected_search_terms": ["proton pump inhibitor", "pH-dependent solubility", "oral anticancer agent", "drug interaction", "pharmacodynamics", "phase III", "exposure response", "separation dosing"]}
{"question": "In rheumatoid arthritis with inadequate response to methotrexate, how does adding a TNF inhibitor compare with adding a JAK inhibitor in improving clinical remission and radiographic progression outcomes?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["rheumatoid arthritis", "methotrexate inadequate response", "TNF inhibitor", "JAK inhibitor", "remission", "radiographic progression", "comparative efficacy"]}
{"question": "In seropositive rheumatoid arthritis, how well do anti-CCP antibody titers predict future development of erosive disease over time?", "topic": "Rheumatoid arthritis", "question_type": "prognosis", "expected_search_terms": ["rheumatoid arthritis", "anti-CCP", "ACPA", "titer", "erosive disease", "radiographic erosion", "prognosis", "cohort"]}
{"question": "Among patients with early rheumatoid arthritis, does a treat-to-target strategy lead to better sustained remission rates than routine care in real-world practice?", "topic": "Rheumatoid arthritis", "question_type": "efficacy_comparison", "expected_search_terms": ["early rheumatoid arthritis", "treat-to-target", "routine care", "sustained remission", "real-world", "observational study"]}
{"question": "In rheumatoid arthritis, what is the association between smoking exposure and the risk of developing anti-citrullinated protein antibody positivity?", "topic": "Rheumatoid arthritis", "question_type": "epidemiology", "expected_search_terms": ["rheumatoid arthritis", "smoking", "cigarette", "anti-citrullinated protein antibody", "ACPA", "anti-CCP", "risk", "epidemiology"]}
{"question": "In rheumatoid arthritis synovium, what evidence supports that NETosis contributes to citrullination and autoantigen generation relevant to disease pathogenesis?", "topic": "Rheumatoid arthritis", "question_type": "mechanism", "expected_search_terms": ["rheumatoid arthritis", "synovium", "NETosis", "neutrophil extracellular traps", "citrullination", "PAD4", "autoantigen", "pathogenesis"]}
{"question": "For rheumatoid arthritis patients on biologic or targeted synthetic DMARDs, how does holding versus continuing therapy around vaccination affect vaccine immunogenicity and disease flare risk?", "topic": "Rheumatoid arthritis", "question_type": "review", "expected_search_terms": ["rheumatoid arthritis", "biologic DMARD", "targeted synthetic DMARD", "vaccination", "immunogenicity", "hold therapy", "continue therapy", "flare"]}
{"question": "In systemic lupus erythematosus, how does adding belimumab to standard therapy compare with standard therapy alone in reducing disease activity and severe flare rates?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "belimumab", "standard therapy", "disease activity", "SLEDAI", "flare", "randomized", "add-on therapy"]}
{"question": "In lupus nephritis induction therapy, how does mycophenolate mofetil compare with cyclophosphamide in achieving complete renal response and minimizing adverse events?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["lupus nephritis", "mycophenolate mofetil", "cyclophosphamide", "induction therapy", "complete renal response", "adverse events"]}
{"question": "In systemic lupus erythematosus, how predictive are low complement levels and anti-dsDNA titers for impending clinical flares in longitudinal studies?", "topic": "Systemic lupus erythematosus", "question_type": "prognosis", "expected_search_terms": ["systemic lupus erythematosus", "complement", "C3", "C4", "anti-dsDNA", "flare prediction", "longitudinal", "biomarkers"]}
{"question": "In systemic lupus erythematosus, what is the relationship between type I interferon gene signature intensity and clinical disease activity across patient cohorts?", "topic": "Systemic lupus erythematosus", "question_type": "mechanism", "expected_search_terms": ["systemic lupus erythematosus", "type I interferon", "interferon signature", "gene expression", "disease activity", "cohort", "biomarker"]}
{"question": "In systemic lupus erythematosus pregnancies, how does hydroxychloroquine use during gestation affect maternal flare rates and neonatal outcomes compared with nonuse?", "topic": "Systemic lupus erythematosus", "question_type": "efficacy_comparison", "expected_search_terms": ["systemic lupus erythematosus", "pregnancy", "hydroxychloroquine", "maternal flare", "neonatal outcomes", "preterm", "preeclampsia"]}
{"question": "Among patients with systemic lupus erythematosus, what is the incidence and relative risk of cardiovascular events compared with matched general population controls?", "topic": "Systemic lupus erythematosus", "question_type": "epidemiology", "expected_search_terms": ["systemic lupus erythematosus", "cardiovascular events", "myocardial infarction", "stroke", "incidence", "relative risk", "population-based"]}
{"question": "In relapsing-remitting multiple sclerosis, how does early initiation of high-efficacy disease-modifying therapy compare with escalation therapy in reducing disability accumulation?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["relapsing-remitting multiple sclerosis", "early high-efficacy therapy", "escalation strategy", "disease-modifying therapy", "disability accumulation", "EDSS", "real-world"]}
{"question": "In multiple sclerosis, how do serum neurofilament light chain levels correlate with relapse risk and MRI activity over follow-up?", "topic": "Multiple sclerosis", "question_type": "prognosis", "expected_search_terms": ["multiple sclerosis", "neurofilament light chain", "serum NfL", "relapse", "MRI activity", "prognostic biomarker", "longitudinal"]}
{"question": "In multiple sclerosis, what evidence supports Epstein-Barr virus infection as a causal or mechanistic contributor to disease onset and progression?", "topic": "Multiple sclerosis", "question_type": "mechanism", "expected_search_terms": ["multiple sclerosis", "Epstein-Barr virus", "EBV", "serology", "risk", "causality", "mechanism", "pathogenesis"]}
{"question": "For multiple sclerosis patients receiving anti-CD20 therapy, how do humoral and cellular responses to vaccination compare with those in patients on other disease-modifying therapies?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["multiple sclerosis", "anti-CD20", "ocrelizumab", "rituximab", "vaccination", "antibody response", "T cell response", "comparison"]}
{"question": "In primary progressive multiple sclerosis, how does anti-CD20 therapy compare with placebo or standard care in slowing disability progression and MRI lesion activity?", "topic": "Multiple sclerosis", "question_type": "efficacy_comparison", "expected_search_terms": ["primary progressive multiple sclerosis", "anti-CD20", "disability progression", "EDSS", "MRI lesion", "randomized controlled trial", "placebo"]}
{"question": "Among people with multiple sclerosis, what is the association between vitamin D status and risk of relapse or new MRI lesions?", "topic": "Multiple sclerosis", "question_type": "epidemiology", "expected_search_terms": ["multiple sclerosis", "vitamin D", "25-hydroxyvitamin D", "relapse risk", "MRI lesions", "observational", "cohort"]}
{"question": "In rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, what factors most consistently predict nonadherence to long-term immunomodulatory therapy?", "topic": "Autoimmune diseases (cross-disease)", "question_type": "review", "expected_search_terms": ["rheumatoid arthritis", "systemic lupus erythematosus", "multiple sclerosis", "medication adherence", "nonadherence", "predictors", "immunomodulatory therapy", "systematic review"]}
{"question": "Across rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, how do chronic glucocorticoid exposure patterns relate to long-term infection risk and mortality?", "topic": "Autoimmune diseases (cross-disease)", "question_type": "prognosis", "expected_search_terms": ["glucocorticoids", "chronic steroid use", "infection risk", "mortality", "rheumatoid arthritis", "systemic lupus erythematosus", "multiple sclerosis", "dose response"]}
{"question": "In mild cognitive impairment due to Alzheimer's disease, how does lecanemab compare with donanemab in slowing cognitive decline and causing amyloid-related imaging abnormalities (ARIA)?", "topic": "Alzheimer's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Alzheimer", "mild cognitive impairment", "lecanemab", "donanemab", "cognitive decline", "ARIA", "amyloid related imaging abnormalities"]}
{"question": "In early Alzheimer's disease, what is the evidence that anti-amyloid monoclonal antibodies reduce downstream tau pathology as measured by tau PET or CSF phosphorylated tau biomarkers?", "topic": "Alzheimer's disease", "question_type": "mechanism", "expected_search_terms": ["Alzheimer", "anti-amyloid", "monoclonal antibody", "tau PET", "CSF phosphorylated tau", "biomarker", "amyloid clearance"]}
{"question": "Among cognitively normal adults, how strongly does APOE ε4 status predict longitudinal amyloid accumulation and subsequent conversion to mild cognitive impairment or Alzheimer's dementia?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["APOE epsilon4", "amyloid PET", "cognitively normal", "conversion", "mild cognitive impairment", "longitudinal", "risk prediction"]}
{"question": "In Alzheimer's disease, how do CSF p-tau217 and plasma p-tau217 compare for diagnostic accuracy in distinguishing Alzheimer's pathology from other neurodegenerative dementias?", "topic": "Alzheimer's disease", "question_type": "review", "expected_search_terms": ["p-tau217", "plasma", "CSF", "diagnostic accuracy", "Alzheimer", "frontotemporal dementia", "Lewy body dementia", "biomarkers"]}
{"question": "In patients with Alzheimer's disease, what is the association between cerebral amyloid angiopathy and the risk of ARIA or intracerebral hemorrhage during anti-amyloid immunotherapy?", "topic": "Alzheimer's disease", "question_type": "prognosis", "expected_search_terms": ["cerebral amyloid angiopathy", "ARIA", "intracerebral hemorrhage", "anti-amyloid", "immunotherapy", "Alzheimer", "risk factors"]}
{"question": "In Parkinson's disease with motor fluctuations, how does subthalamic nucleus deep brain stimulation compare with globus pallidus interna stimulation for improving dyskinesia and quality of life?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson", "deep brain stimulation", "subthalamic nucleus", "globus pallidus interna", "dyskinesia", "quality of life", "motor fluctuations"]}
{"question": "In Parkinson's disease, what evidence supports gut microbiome alterations as contributors to alpha-synuclein aggregation and neuroinflammation in the gut-brain axis?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["Parkinson", "gut microbiome", "alpha-synuclein", "aggregation", "neuroinflammation", "gut brain axis", "enteric nervous system"]}
{"question": "In early Parkinson's disease, how do MAO-B inhibitors compare with dopamine agonists as initial therapy in delaying levodopa initiation and causing neuropsychiatric adverse effects?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson", "early", "MAO-B inhibitor", "rasagiline", "selegiline", "dopamine agonist", "levodopa delay", "impulse control", "hallucinations"]}
{"question": "In Parkinson's disease, what is the prognostic value of REM sleep behavior disorder for subsequent cognitive decline and development of dementia?", "topic": "Parkinson's disease", "question_type": "prognosis", "expected_search_terms": ["Parkinson", "REM sleep behavior disorder", "cognitive decline", "dementia", "prognosis", "longitudinal cohort"]}
{"question": "In Parkinson's disease psychosis, how does pimavanserin compare with atypical antipsychotics in reducing hallucinations without worsening motor symptoms?", "topic": "Parkinson's disease", "question_type": "efficacy_comparison", "expected_search_terms": ["Parkinson", "psychosis", "pimavanserin", "quetiapine", "clozapine", "hallucinations", "motor worsening", "UPDRS"]}
{"question": "In Parkinson's disease, what are the reported relationships between LRRK2 kinase activity, neuroinflammation markers, and dopaminergic neuron degeneration in human and translational studies?", "topic": "Parkinson's disease", "question_type": "mechanism", "expected_search_terms": ["LRRK2", "kinase activity", "Parkinson", "neuroinflammation", "microglia", "dopaminergic degeneration", "biomarkers"]}
{"question": "In refractory focal epilepsy, how does vagus nerve stimulation compare with responsive neurostimulation in seizure frequency reduction and patient-reported quality of life?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["refractory focal epilepsy", "vagus nerve stimulation", "VNS", "responsive neurostimulation", "RNS", "seizure frequency", "quality of life"]}
{"question": "In newly diagnosed focal epilepsy, how do levetiracetam and lamotrigine compare in long-term seizure freedom and psychiatric adverse effects such as irritability or depression?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["newly diagnosed", "focal epilepsy", "levetiracetam", "lamotrigine", "seizure freedom", "depression", "irritability", "adverse effects"]}
{"question": "In temporal lobe epilepsy, what is the evidence that blood-brain barrier dysfunction contributes to seizure generation through albumin extravasation and astrocytic TGF-β signaling?", "topic": "Epilepsy", "question_type": "mechanism", "expected_search_terms": ["temporal lobe epilepsy", "blood brain barrier", "albumin extravasation", "TGF-beta", "astrocytes", "epileptogenesis", "mechanism"]}
{"question": "In pediatric epilepsy, what is the incidence of sudden unexpected death in epilepsy (SUDEP) and which clinical factors most consistently predict increased risk?", "topic": "Epilepsy", "question_type": "epidemiology", "expected_search_terms": ["pediatric epilepsy", "SUDEP", "incidence", "risk factors", "generalized tonic-clonic seizures", "nocturnal seizures", "population study"]}
{"question": "After a first unprovoked seizure in adults, how accurately do EEG abnormalities and brain MRI findings predict seizure recurrence within two years?", "topic": "Epilepsy", "question_type": "prognosis", "expected_search_terms": ["first unprovoked seizure", "EEG", "MRI", "recurrence", "two-year", "prediction", "adult"]}
{"question": "In drug-resistant epilepsy, what is the comparative effectiveness of ketogenic diet versus modified Atkins diet on seizure reduction and tolerability in adolescents and adults?", "topic": "Epilepsy", "question_type": "efficacy_comparison", "expected_search_terms": ["drug-resistant epilepsy", "ketogenic diet", "modified Atkins", "adolescents", "adults", "seizure reduction", "tolerability"]}
{"question": "In Alzheimer's disease, how does long-term exposure to anticholinergic medications relate to incident dementia risk and trajectories of cognitive decline in observational cohorts?", "topic": "Alzheimer's disease", "question_type": "epidemiology", "expected_search_terms": ["anticholinergic", "medication exposure", "incident dementia", "Alzheimer", "cognitive decline", "cohort", "risk"]}
{"question": "In Parkinson's disease, what is the association between pesticide exposure (such as paraquat or rotenone) and disease incidence in case-control or cohort studies?", "topic": "Parkinson's disease", "question_type": "epidemiology", "expected_search_terms": ["Parkinson", "pesticide exposure", "paraquat", "rotenone", "incidence", "case-control", "cohort"]}
{"question": "Across Alzheimer's disease, Parkinson's disease, and epilepsy, what evidence supports neuroinflammation markers (such as TSPO PET or CSF cytokines) as predictors of disease progression or treatment response?", "topic": "Cross-disorder (Alzheimer's/Parkinson's/Epilepsy)", "question_type": "review", "expected_search_terms": ["neuroinflammation", "TSPO PET", "CSF cytokines", "disease progression", "treatment response", "Alzheimer", "Parkinson", "epilepsy"]}
{"question": "In sickle cell disease, how do clinical outcomes and safety profiles compare between ex vivo CRISPR-based BCL11A enhancer editing of autologous hematopoietic stem cells and lentiviral gene addition approaches targeting hemoglobin induction?", "topic": "Gene therapy for hemoglobinopathies", "question_type": "efficacy_comparison", "expected_search_terms": ["sickle cell disease", "CRISPR", "BCL11A enhancer", "hematopoietic stem cell", "lentiviral", "gene addition", "fetal hemoglobin", "clinical trial"]}
{"question": "For transfusion-dependent beta-thalassemia, what is the comparative durability of transfusion independence and long-term adverse events between CRISPR-edited autologous HSC therapy and viral vector-based gene therapy?", "topic": "Gene therapy for beta-thalassemia", "question_type": "efficacy_comparison", "expected_search_terms": ["beta-thalassemia", "transfusion dependent", "CRISPR", "gene editing", "autologous hematopoietic stem cell", "lentiviral", "transfusion independence", "long-term follow-up"]}
{"question": "In hereditary transthyretin amyloidosis, how do efficacy and safety outcomes compare between in vivo CRISPR lipid nanoparticle editing of TTR and RNA interference-based TTR knockdown therapies?", "topic": "In vivo gene editing for amyloidosis", "question_type": "efficacy_comparison", "expected_search_terms": ["transthyretin amyloidosis", "TTR", "in vivo CRISPR", "lipid nanoparticle", "gene editing", "RNA interference", "siRNA", "neuropathy outcomes"]}
{"question": "In Leber congenital amaurosis caused by RPE65 variants, what is the long-term visual function durability and safety profile of subretinal AAV gene replacement therapy in real-world follow-up cohorts?", "topic": "Retinal gene therapy", "question_type": "prognosis", "expected_search_terms": ["Leber congenital amaurosis", "RPE65", "AAV", "gene therapy", "subretinal", "visual acuity", "visual field", "long-term safety"]}
{"question": "In hemophilia A, how do factor VIII expression durability and hepatotoxicity risks compare between AAV-mediated gene transfer and emerging non-viral gene editing strategies targeting the liver?", "topic": "Liver-directed gene therapy for hemophilia", "question_type": "efficacy_comparison", "expected_search_terms": ["hemophilia A", "factor VIII", "AAV", "gene transfer", "liver-directed", "gene editing", "hepatotoxicity", "transaminitis"]}
{"question": "In hemophilia B, what clinical and immunologic factors predict loss of factor IX expression after AAV gene therapy during long-term follow-up?", "topic": "Predictors of gene therapy durability", "question_type": "prognosis", "expected_search_terms": ["hemophilia B", "factor IX", "AAV", "gene therapy", "durability", "predictors", "capsid immunity", "transaminitis", "long-term follow-up"]}
{"question": "What are the predominant mechanisms underlying hepatocellular injury after AAV-mediated liver gene transfer in humans, and how do they relate to capsid-specific T cell responses versus innate immune activation?", "topic": "Mechanisms of AAV-associated toxicity", "question_type": "mechanism", "expected_search_terms": ["AAV", "gene therapy", "hepatotoxicity", "transaminitis", "capsid-specific T cells", "innate immunity", "cytokines", "human"]}
{"question": "How do pre-existing neutralizing antibodies to AAV capsids affect transduction efficacy and safety across different systemic gene therapy indications, and what titer thresholds are clinically meaningful?", "topic": "AAV immunogenicity and patient selection", "question_type": "review", "expected_search_terms": ["AAV", "neutralizing antibodies", "pre-existing immunity", "gene therapy", "transduction", "clinical outcomes", "titer threshold"]}
{"question": "In CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, how do CRISPR-edited allogeneic CAR-T products compare with autologous CAR-T products in rates of response, cytokine release syndrome, and graft-versus-host disease?", "topic": "CRISPR-engineered cellular immunotherapy", "question_type": "efficacy_comparison", "expected_search_terms": ["B-cell acute lymphoblastic leukemia", "CAR-T", "allogeneic", "CRISPR", "gene edited", "autologous", "cytokine release syndrome", "graft versus host disease"]}
{"question": "In solid tumors, what tumor-intrinsic and microenvironmental mechanisms limit persistence and trafficking of engineered T cells, and which genetic edits have shown evidence of improving these barriers in early clinical studies?", "topic": "Mechanisms limiting cell therapy in solid tumors", "question_type": "mechanism", "expected_search_terms": ["solid tumor", "engineered T cells", "CAR-T", "TCR-T", "persistence", "trafficking", "tumor microenvironment", "gene editing", "clinical"]}
{"question": "What is the incidence and spectrum of insertional mutagenesis or clonal expansion signals observed in patients receiving integrating viral vector gene therapies, and how does risk vary by vector type and target cell population?", "topic": "Genotoxicity of integrating vectors", "question_type": "epidemiology", "expected_search_terms": ["insertional mutagenesis", "clonal expansion", "lentiviral", "retroviral", "gene therapy", "genotoxicity", "long-term follow-up", "hematopoietic stem cells"]}
{"question": "Among ex vivo CRISPR-edited hematopoietic stem cell therapies, what off-target detection methods are most predictive of clinically relevant genomic alterations in manufactured cell products?", "topic": "Off-target assessment in ex vivo editing", "question_type": "review", "expected_search_terms": ["CRISPR", "off-target", "hematopoietic stem cell", "ex vivo", "GUIDE-seq", "CIRCLE-seq", "DISCOVER-seq", "whole genome sequencing", "safety"]}
{"question": "How do base editing and prime editing differ in on-target efficiency and unintended byproducts (such as indels or bystander edits) in therapeutically relevant human cell types used for cell therapy manufacturing?", "topic": "Next-generation gene editing modalities", "question_type": "mechanism", "expected_search_terms": ["base editing", "prime editing", "on-target efficiency", "bystander edit", "indels", "human cells", "cell therapy manufacturing"]}
{"question": "In Duchenne muscular dystrophy, what evidence supports exon-skipping via AAV-delivered microdystrophin gene therapy versus CRISPR-based dystrophin restoration in terms of functional outcomes and cardiac safety signals?", "topic": "Gene therapy and editing for DMD", "question_type": "efficacy_comparison", "expected_search_terms": ["Duchenne muscular dystrophy", "microdystrophin", "AAV", "gene therapy", "CRISPR", "dystrophin restoration", "functional outcome", "cardiac", "safety"]}
{"question": "What are the mechanistic explanations for variable patient response to in vivo gene editing therapies, including delivery efficiency, DNA repair pathway choice, and target tissue cell turnover?", "topic": "Determinants of in vivo editing response", "question_type": "mechanism", "expected_search_terms": ["in vivo gene editing", "delivery efficiency", "DNA repair", "NHEJ", "HDR", "cell turnover", "response variability"]}
{"question": "In spinal muscular atrophy, how does long-term motor function and survival compare between systemic AAV gene replacement therapy and intrathecal antisense oligonucleotide therapy in treated pediatric cohorts?", "topic": "Gene therapy vs molecular therapy in SMA", "question_type": "efficacy_comparison", "expected_search_terms": ["spinal muscular atrophy", "AAV", "gene replacement", "SMN1", "antisense oligonucleotide", "intrathecal", "motor function", "survival", "long-term"]}
{"question": "What is the incidence and clinical course of thrombotic microangiopathy following systemic AAV gene therapies, and what patient or treatment factors are associated with higher risk?", "topic": "Systemic AAV adverse event epidemiology", "question_type": "epidemiology", "expected_search_terms": ["AAV", "gene therapy", "thrombotic microangiopathy", "TMA", "incidence", "risk factors", "complement", "case series"]}
{"question": "In Parkinson disease models and early clinical research, how do transplanted dopaminergic neurons derived from pluripotent stem cells integrate functionally, and what are the main mechanisms of graft survival and immune rejection?", "topic": "Stem cell-derived neuronal transplantation", "question_type": "mechanism", "expected_search_terms": ["Parkinson disease", "pluripotent stem cell", "iPSC", "dopaminergic neurons", "transplantation", "graft survival", "immune rejection", "integration"]}
{"question": "For type 1 diabetes, what clinical evidence supports the efficacy and safety of stem cell-derived islet cell replacement with immune-evasion strategies (such as encapsulation or gene-edited HLA modulation) in achieving insulin independence?", "topic": "Cell replacement therapy for diabetes", "question_type": "efficacy_comparison", "expected_search_terms": ["type 1 diabetes", "stem cell-derived islets", "beta cell replacement", "encapsulation", "HLA gene editing", "immune evasion", "insulin independence", "clinical"]}
{"question": "What are the leading strategies to reduce immunogenicity of gene-edited or gene-modified cell therapies, and what human data exist on their impact on persistence and adverse immune events?", "topic": "Immunogenicity mitigation in gene/cell therapy", "question_type": "review", "expected_search_terms": ["gene-modified cells", "gene-edited", "immunogenicity", "immune evasion", "HLA knockout", "beta-2 microglobulin", "persistence", "human data"]}
{"question": "In first-line treatment of metastatic non-small cell lung cancer with high PD-L1 expression, how does PD-1/PD-L1 inhibitor monotherapy compare with PD-1/PD-L1 inhibitor plus platinum-doublet chemotherapy in overall survival and grade 3–4 adverse events?", "topic": "PD-1/PD-L1 inhibitors in NSCLC", "question_type": "efficacy_comparison", "expected_search_terms": ["non-small cell lung cancer", "high PD-L1", "PD-1 inhibitor", "PD-L1 inhibitor", "monotherapy", "chemoimmunotherapy", "overall survival", "grade 3-4 adverse events", "first-line"]}
{"question": "In unresectable hepatocellular carcinoma, how does anti-PD-1/PD-L1 plus anti-VEGF therapy compare with anti-PD-1/PD-L1 plus CTLA-4 blockade in objective response rate and immune-related toxicity?", "topic": "Combination immunotherapy in HCC", "question_type": "efficacy_comparison", "expected_search_terms": ["hepatocellular carcinoma", "PD-1", "PD-L1", "VEGF", "bevacizumab", "CTLA-4", "combination therapy", "objective response rate", "immune-related adverse events"]}
{"question": "In metastatic melanoma, what biomarkers best predict benefit from PD-1 inhibitor monotherapy versus PD-1 plus CTLA-4 combination therapy?", "topic": "Predictive biomarkers for checkpoint therapy", "question_type": "review", "expected_search_terms": ["metastatic melanoma", "PD-1", "CTLA-4", "combination", "biomarkers", "predictive", "tumor mutational burden", "PD-L1", "gene expression signature"]}
{"question": "Across solid tumors, how consistently does tumor mutational burden correlate with response to PD-1/PD-L1 inhibitors when controlling for PD-L1 expression or immune-inflamed gene signatures?", "topic": "TMB and response to PD-1/PD-L1", "question_type": "mechanism", "expected_search_terms": ["tumor mutational burden", "PD-1", "PD-L1", "response", "PD-L1 expression", "immune gene signature", "inflamed", "predictive biomarker", "solid tumors"]}
{"question": "In patients receiving immune checkpoint inhibitors, what is the association between baseline antibiotic exposure and objective response rate or survival outcomes?", "topic": "Microbiome-modifying exposures and ICI outcomes", "question_type": "prognosis", "expected_search_terms": ["immune checkpoint inhibitor", "antibiotics", "baseline exposure", "microbiome", "objective response", "progression-free survival", "overall survival"]}
{"question": "In solid tumors treated with PD-1/PD-L1 inhibitors, how do intratumoral CD8+ T-cell density and spatial proximity to tumor cells relate to treatment response?", "topic": "Tumor microenvironment spatial immunology", "question_type": "mechanism", "expected_search_terms": ["PD-1", "PD-L1", "CD8 T cells", "spatial", "tumor microenvironment", "immunohistochemistry", "multiplex immunofluorescence", "treatment response"]}
{"question": "In CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma, how do CD28 versus 4-1BB costimulatory domains compare in durability of response and rates of cytokine release syndrome?", "topic": "CAR-T design in DLBCL", "question_type": "efficacy_comparison", "expected_search_terms": ["CAR-T", "diffuse large B-cell lymphoma", "CD28", "4-1BB", "costimulatory domain", "durable response", "cytokine release syndrome", "relapsed refractory"]}
{"question": "In CAR-T therapy, what tumor-intrinsic or microenvironmental mechanisms are most strongly linked to antigen escape and subsequent relapse?", "topic": "CAR-T resistance mechanisms", "question_type": "mechanism", "expected_search_terms": ["CAR-T", "antigen escape", "relapse", "resistance mechanisms", "tumor microenvironment", "lineage switch", "antigen loss", "immune evasion"]}
{"question": "In B-cell acute lymphoblastic leukemia treated with CD19 CAR-T cells, which pre-infusion disease and immune parameters are most predictive of severe cytokine release syndrome or neurotoxicity?", "topic": "CAR-T toxicity predictors", "question_type": "prognosis", "expected_search_terms": ["CD19 CAR-T", "B-ALL", "cytokine release syndrome", "ICANS", "predictors", "tumor burden", "ferritin", "cytokines", "baseline inflammation"]}
{"question": "In solid tumor CAR-T trials, how does regional delivery (intratumoral or intracavitary) compare with systemic infusion in terms of tumor trafficking and on-target off-tumor toxicity?", "topic": "CAR-T delivery routes in solid tumors", "question_type": "efficacy_comparison", "expected_search_terms": ["CAR-T", "solid tumor", "intratumoral", "intracavitary", "regional delivery", "systemic infusion", "trafficking", "on-target off-tumor toxicity"]}
{"question": "In patients treated with PD-1/PD-L1 inhibitors, what is the incidence and typical time-to-onset of myocarditis, and which clinical factors are associated with higher risk?", "topic": "Immune-related myocarditis epidemiology", "question_type": "epidemiology", "expected_search_terms": ["PD-1", "PD-L1", "immune checkpoint inhibitor", "myocarditis", "incidence", "time to onset", "risk factors", "immune-related adverse events"]}
{"question": "In metastatic renal cell carcinoma, how does first-line PD-1 inhibitor plus VEGF tyrosine kinase inhibitor compare with PD-1 plus CTLA-4 blockade in progression-free survival and discontinuation due to toxicity?", "topic": "First-line immunotherapy in RCC", "question_type": "efficacy_comparison", "expected_search_terms": ["renal cell carcinoma", "first-line", "PD-1", "VEGF TKI", "axitinib", "cabozantinib", "CTLA-4", "progression-free survival", "treatment discontinuation"]}
{"question": "In urothelial carcinoma treated with PD-1/PD-L1 inhibitors, how do different PD-L1 assay platforms and scoring systems affect patient selection and reported response rates?", "topic": "PD-L1 testing variability", "question_type": "review", "expected_search_terms": ["urothelial carcinoma", "PD-L1 assay", "immunohistochemistry", "CPS", "TPS", "SP142", "22C3", "28-8", "response rate"]}
{"question": "In patients receiving immune checkpoint inhibitors, how does baseline corticosteroid use for cancer-related symptoms influence treatment efficacy and survival outcomes?", "topic": "Concomitant medications and ICI efficacy", "question_type": "prognosis", "expected_search_terms": ["immune checkpoint inhibitor", "corticosteroids", "baseline steroid", "cancer-related symptoms", "overall survival", "progression-free survival", "treatment response"]}
{"question": "In microsatellite instability-high (MSI-H) metastatic colorectal cancer, how does PD-1 inhibitor monotherapy compare with PD-1 plus CTLA-4 combination therapy in objective response and immune-related colitis?", "topic": "Checkpoint strategies in MSI-H CRC", "question_type": "efficacy_comparison", "expected_search_terms": ["MSI-H", "metastatic colorectal cancer", "PD-1 inhibitor", "CTLA-4", "combination", "objective response", "immune-related colitis"]}
{"question": "In solid tumors treated with PD-1/PD-L1 blockade, what is the evidence that tumor-associated macrophage polarization (M1/M2) influences resistance, and which pathways are most implicated?", "topic": "Macrophages in the tumor microenvironment", "question_type": "mechanism", "expected_search_terms": ["tumor-associated macrophages", "M2", "M1", "PD-1", "PD-L1", "resistance", "CSF1R", "TGF-beta", "myeloid suppression"]}
{"question": "In patients with pre-existing autoimmune disease who receive PD-1/PD-L1 inhibitors, what are the rates of autoimmune flare versus de novo immune-related adverse events, and how often does treatment discontinuation occur?", "topic": "ICI safety in autoimmune disease", "question_type": "epidemiology", "expected_search_terms": ["pre-existing autoimmune disease", "PD-1", "PD-L1", "immune checkpoint inhibitor", "autoimmune flare", "immune-related adverse events", "treatment discontinuation"]}
{"question": "In triple-negative breast cancer, how does adding a PD-1/PD-L1 inhibitor to chemotherapy affect pathological complete response rates in early-stage disease and progression-free survival in metastatic disease?", "topic": "Checkpoint inhibitors in TNBC across settings", "question_type": "efficacy_comparison", "expected_search_terms": ["triple-negative breast cancer", "PD-1", "PD-L1", "chemotherapy", "pathologic complete response", "early-stage", "metastatic", "progression-free survival"]}
{"question": "In patients treated with immune checkpoint inhibitors, how does the development of vitiligo or other skin immune-related adverse events correlate with tumor response and survival in melanoma?", "topic": "irAEs as prognostic markers", "question_type": "prognosis", "expected_search_terms": ["melanoma", "immune checkpoint inhibitor", "vitiligo", "cutaneous immune-related adverse events", "tumor response", "overall survival", "progression-free survival"]}
{"question": "In cancer immunotherapy, what mechanisms explain acquired resistance to PD-1/PD-L1 blockade related to interferon signaling and antigen presentation defects?", "topic": "Acquired resistance to checkpoint blockade", "question_type": "mechanism", "expected_search_terms": ["acquired resistance", "PD-1", "PD-L1", "interferon gamma signaling", "JAK1", "JAK2", "beta-2 microglobulin", "antigen presentation", "MHC class I"]}
{"question": "In patients with heart failure with reduced ejection fraction, how does SGLT2 inhibitor therapy compare with angiotensin receptor–neprilysin inhibitor therapy in reducing cardiovascular death and heart failure hospitalization?", "topic": "Heart Failure (HFrEF)", "question_type": "efficacy_comparison", "expected_search_terms": ["HFrEF", "SGLT2 inhibitor", "sacubitril valsartan", "angiotensin receptor neprilysin inhibitor", "cardiovascular mortality", "heart failure hospitalization", "randomized trial"]}
{"question": "In heart failure with preserved ejection fraction, what is the magnitude of benefit of SGLT2 inhibitors on symptoms and heart failure hospitalization, and does it vary by left ventricular ejection fraction subgroup?", "topic": "Heart Failure (HFpEF)", "question_type": "efficacy_comparison", "expected_search_terms": ["HFpEF", "SGLT2 inhibitor", "ejection fraction subgroup", "KCCQ", "quality of life", "heart failure hospitalization", "meta-analysis"]}
{"question": "Among patients with symptomatic atrial fibrillation, how does catheter ablation compare with antiarrhythmic drug therapy for preventing AF recurrence and improving quality of life?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "catheter ablation", "antiarrhythmic drugs", "recurrence", "quality of life", "randomized controlled trial"]}
{"question": "In patients with atrial fibrillation and high stroke risk, how do direct oral anticoagulants compare with warfarin for preventing ischemic stroke while minimizing major bleeding in real-world populations?", "topic": "Atrial Fibrillation", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "direct oral anticoagulant", "warfarin", "ischemic stroke", "major bleeding", "observational study", "propensity score"]}
{"question": "In stable coronary artery disease, does adding a PCSK9 inhibitor to high-intensity statin therapy reduce major adverse cardiovascular events more than statin therapy alone?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["stable coronary artery disease", "PCSK9 inhibitor", "high-intensity statin", "major adverse cardiovascular events", "LDL cholesterol", "randomized trial"]}
{"question": "After acute coronary syndrome, how does dual antiplatelet therapy with ticagrelor compare with clopidogrel in reducing recurrent myocardial infarction and all-cause mortality, accounting for bleeding risk?", "topic": "Coronary Artery Disease (ACS)", "question_type": "efficacy_comparison", "expected_search_terms": ["acute coronary syndrome", "ticagrelor", "clopidogrel", "dual antiplatelet therapy", "myocardial infarction", "mortality", "bleeding"]}
{"question": "In patients with coronary artery disease and elevated triglycerides, what is the effect of icosapent ethyl on cardiovascular outcomes compared with placebo on top of statin therapy?", "topic": "Coronary Artery Disease", "question_type": "efficacy_comparison", "expected_search_terms": ["coronary artery disease", "icosapent ethyl", "eicosapentaenoic acid", "triglycerides", "statin", "cardiovascular outcomes", "randomized trial"]}
{"question": "In chronic heart failure, what is the association between iron deficiency and exercise capacity, and does intravenous iron therapy improve functional status compared with oral iron or placebo?", "topic": "Heart Failure", "question_type": "efficacy_comparison", "expected_search_terms": ["heart failure", "iron deficiency", "intravenous iron", "ferric carboxymaltose", "exercise capacity", "6-minute walk", "functional class"]}
{"question": "In atrial fibrillation patients undergoing percutaneous coronary intervention, how does dual therapy (DOAC plus P2Y12 inhibitor) compare with triple therapy (anticoagulant plus aspirin plus P2Y12 inhibitor) for bleeding and ischemic outcomes?", "topic": "Atrial Fibrillation + Coronary Intervention", "question_type": "efficacy_comparison", "expected_search_terms": ["atrial fibrillation", "percutaneous coronary intervention", "dual therapy", "triple therapy", "P2Y12 inhibitor", "bleeding", "stent thrombosis"]}
{"question": "What mechanisms link chronic systemic inflammation to atherosclerotic plaque instability and acute coronary syndromes?", "topic": "Coronary Artery Disease", "question_type": "mechanism", "expected_search_terms": ["atherosclerosis", "plaque instability", "inflammation", "IL-1 beta", "IL-6", "NLRP3 inflammasome", "acute coronary syndrome", "pathophysiology"]}
{"question": "How does atrial fibrosis contribute to atrial fibrillation maintenance, and what molecular pathways are most consistently implicated in human atrial tissue studies?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["atrial fibrillation", "atrial fibrosis", "TGF-beta", "extracellular matrix", "fibroblast activation", "human atrial tissue", "mechanisms"]}
{"question": "What is the evidence that epicardial adipose tissue contributes to atrial fibrillation via local inflammatory or electrophysiologic effects?", "topic": "Atrial Fibrillation", "question_type": "mechanism", "expected_search_terms": ["epicardial adipose tissue", "atrial fibrillation", "inflammation", "adipokines", "electrophysiology", "atrial remodeling", "imaging"]}
{"question": "What mechanisms explain the benefits of SGLT2 inhibitors in heart failure independent of glucose lowering, based on clinical biomarker and mechanistic studies?", "topic": "Heart Failure", "question_type": "mechanism", "expected_search_terms": ["SGLT2 inhibitors", "heart failure", "mechanism", "natriuresis", "ketone metabolism", "cardiorenal", "biomarkers", "myocardial energetics"]}
{"question": "What is the global and regional prevalence of atrial fibrillation, and how has it changed over the past two decades across age and sex strata?", "topic": "Atrial Fibrillation", "question_type": "epidemiology", "expected_search_terms": ["atrial fibrillation", "prevalence", "incidence", "global", "regional", "time trends", "age", "sex"]}
{"question": "Among patients with stable coronary artery disease, what is the incidence of myocardial infarction after discontinuation of long-term aspirin therapy compared with continuation?", "topic": "Coronary Artery Disease", "question_type": "epidemiology", "expected_search_terms": ["stable coronary artery disease", "aspirin discontinuation", "myocardial infarction", "secondary prevention", "cohort study", "risk"]}
{"question": "In heart failure populations, how common is frailty and how strongly is it associated with hospitalization and mortality independent of age and comorbidity burden?", "topic": "Heart Failure", "question_type": "prognosis", "expected_search_terms": ["heart failure", "frailty", "hospitalization", "mortality", "prognosis", "frailty index", "meta-analysis"]}
{"question": "In atrial fibrillation, how well do left atrial size and left atrial strain predict incident stroke or systemic embolism beyond standard clinical risk scores?", "topic": "Atrial Fibrillation", "question_type": "prognosis", "expected_search_terms": ["atrial fibrillation", "left atrial strain", "left atrial size", "echocardiography", "stroke prediction", "CHA2DS2-VASc", "systemic embolism"]}
{"question": "After myocardial infarction, what is the prognostic value of residual inflammatory risk measured by high-sensitivity C-reactive protein for recurrent events despite optimal lipid lowering?", "topic": "Coronary Artery Disease (Post-MI)", "question_type": "prognosis", "expected_search_terms": ["myocardial infarction", "hsCRP", "residual inflammatory risk", "recurrent cardiovascular events", "statin", "prognosis"]}
{"question": "In patients with ischemic cardiomyopathy, how does myocardial viability assessment by cardiac MRI or PET relate to outcomes after coronary revascularization compared with medical therapy?", "topic": "Coronary Artery Disease + Heart Failure", "question_type": "prognosis", "expected_search_terms": ["ischemic cardiomyopathy", "myocardial viability", "cardiac MRI", "PET", "revascularization", "medical therapy", "mortality", "heart failure outcomes"]}
{"question": "What is the current evidence on the effectiveness of structured cardiac rehabilitation in reducing mortality and rehospitalization after acute coronary syndrome or heart failure hospitalization?", "topic": "Coronary Artery Disease and Heart Failure", "question_type": "review", "expected_search_terms": ["cardiac rehabilitation", "acute coronary syndrome", "heart failure", "mortality", "rehospitalization", "systematic review", "meta-analysis"]}
